BMO Capital Markets Analysts Give Bristol-Myers Squibb (BMY) a $51.00 Price Target

Bristol-Myers Squibb (NYSE:BMY) received a $51.00 price target from BMO Capital Markets in a research note issued on Wednesday. The firm currently has a “sell” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective indicates a potential downside of 21.62% from the company’s previous close.

Several other research analysts also recently weighed in on the company. Zacks Investment Research downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Vetr downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 price objective for the company. in a report on Thursday, December 28th. SunTrust Banks upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. Leerink Swann upped their price objective on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a report on Monday, October 23rd. Finally, Citigroup set a $72.00 price objective on Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Tuesday, December 5th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $65.58.

Shares of Bristol-Myers Squibb (BMY) traded up $1.20 on Wednesday, reaching $65.07. The company’s stock had a trading volume of 4,953,375 shares, compared to its average volume of 8,476,972. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. The firm has a market cap of $106,530.00, a P/E ratio of 110.68, a PEG ratio of 1.96 and a beta of 1.08. Bristol-Myers Squibb has a 52 week low of $51.56 and a 52 week high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.01. The company had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a return on equity of 33.68% and a net margin of 4.85%. Bristol-Myers Squibb’s revenue was up 3.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.63 EPS. research analysts anticipate that Bristol-Myers Squibb will post 3.22 earnings per share for the current year.

In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the transaction, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Sandra Leung sold 156,582 shares of the stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the transaction, the executive vice president now directly owns 584,373 shares in the company, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

Several hedge funds have recently modified their holdings of BMY. Delphi Private Advisors LLC bought a new position in Bristol-Myers Squibb in the fourth quarter worth about $108,000. Massey Quick Simon & CO. LLC lifted its holdings in Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 1,492 shares during the last quarter. Horan Capital Advisors LLC. bought a new position in Bristol-Myers Squibb in the third quarter worth about $122,000. NuWave Investment Management LLC bought a new position in Bristol-Myers Squibb in the fourth quarter worth about $119,000. Finally, Tradewinds Capital Management LLC increased its stake in shares of Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 500 shares during the period. 69.56% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/02/14/bmo-capital-markets-analysts-give-bristol-myers-squibb-bmy-a-51-00-price-target.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply